Clarassance is a privately-held, clinical-stage Delaware Corporation headquartered in Rockville, Maryland.
Our mission is to develop biopharmaceutical products based on the unique family of proteins called
secretoglobins.  There are several secretoglobins made in the human body, the most abundant of which is
called CC10.  CC10 is a potent anti-inflammatory agent that may bring benefit in many types of disease.   

Several respiratory and autoimmune diseases may be caused, at least in part, by a lack of sufficient native
CC10 protein in the patients.  Replacement of CC10 with the recombinant version (rhCC10) in respiratory
diseases characterized by inflammation and pre-existing CC10 deficiency is the central therapeutic strategy.
Restoration of CC10 function using rhCC10 has the potential to modify, or even rehabilitate, airways in
diseases like asthma, chronic or recurrent sinusitis, COPD, and pulmonary fibrosis, rather than just treat the
symptoms. RhCC10 has completed two Phase 1 clinical trials in which it was safe and even showed potent
anti-inflammatory activity and significant long term benefit in premature infants, who are known to lack
sufficient native CC10 in their lungs.
In recent news